Adriamycin: The Therapeutic Activity on Experimental Tumors

  • A. Di Marco


Adriamycin is a new antibiotic isolated from the cultures of a mutant strain of S. Peucetius, called. S. Peucetius var. caesius and shown to be highly active in inhibiting the growth of Ehrlich ascites tumor (Arcamone, Cassinelli, Di Marco, and Gaetani, 1969).


Therapeutic Activity Experimental Tumor Radioactivity Level Methyl Green Ehrlich Ascites Tumor 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. Arcamone, F., Cassinelli, G., Di Marco, A., Gaetani, M.: Patent Application, Farmitalia Research Laboratories, 1969.Google Scholar
  2. Arcamone, F., Cassinelli, G., Franceschi, G., Orezzi, P., Penco, S., Selva, A.: La struttura della adriamicina nuovo antibiotico antitumorale. Symposium Internazionale Adriamicina, 71° Convegno Farmitalia, 1971.Google Scholar
  3. Bachur, N.R.: J. Pharmacol, exp. Ther. 177,573 (1971).Google Scholar
  4. Casazza, A. M., Scarpinato, B. M., Di Cuonzo, G.: Activity of adriamycin and daunomycin on primary and transplantable Moloney Sarcoma Virus-induced tumors in mice. 10th International Cancer Congress, Houston, May 22–. Abstracts, pp. 391,1970.Google Scholar
  5. Di Fronzo, G., Gambetta, R. A., Lenaz, L.: Rev. Europ. Etud. Clin. Biol. 16, 572 (1971).Google Scholar
  6. Di Marco, A.: Daunomycin and related antibiotics. Antibiotics-Vol. 1, Mechanism of action, 1967.Google Scholar
  7. Di Marco, A., Boretti, G., Rusconi, A.: Il farmaco, 22, 535 (1967).Google Scholar
  8. Di Marco, A., Gaetani, M., Scarpinato, B. M.: Cancer Chemother., Rep. 53, 33 (1969).Google Scholar
  9. Di Marco, A., Lenaz, L.: Daunomycin and adriamycin. Cancer Med. (in press).Google Scholar
  10. Di Marco, A., Lenaz, L., Casazza, A. M., Scarpinato, B. M.: Activity of adriamycin (NSC-123, 127) and daunomycin (NSC-82151) on mouse mammary carcinoma. Cancer Chemother. Rep. (in press).Google Scholar
  11. Di Marco, A., Lenaz, L., Scarpinato, B. M.: Protezione immunologica legata al sesso nel carcinoma mammario murino Congresso di Cancerologia, Cagliari 8–9 Ottobre 1971.Google Scholar
  12. Di Marco, A., Zunino, F., Gambetta, R. A.: Unpublished data.Google Scholar
  13. Di Marco, A., Zunino, F., Silvestrini, R., Gambarucci, C., Gambetta, R. A.: Biochem. Pharmacol. 20, 1323 (1971).PubMedCrossRefGoogle Scholar
  14. Necco, A., Dasdia, T.: Unpublished data, 1971.Google Scholar
  15. Sandberg, S. J., Howsden, F. L., Di Marco, A., Goldin, A.: Cancer Chemother. Rep. 51, 1 (1970).Google Scholar
  16. Scholler, J., Philips, F. S., Sternberg, S. S., Bittner, J. J.: Cancer 9, 240 (1956).PubMedCrossRefGoogle Scholar
  17. Silvestrini, R., Gambarucci, C., Dasdia, T.: Attività biologica dell’adriamicina “in vitro”. Tumori 56, Nr. 3 (1970).Google Scholar
  18. Skipper, H. E., Schmidt, L. H.: Cancer Chemother. Rep. 17, 179 (1962).Google Scholar

Copyright information

© Springer-Verlag, Berlin Heidelberg 1972

Authors and Affiliations

  • A. Di Marco
    • 1
  1. 1.Istituto Nazionale per lo Studio e la Cura dei TumoriDivisione Oncologia Sperimentale B1-MilanoItaly

Personalised recommendations